The Efficacy and Adverse Effects of SORAFENIB in patiants of Hepatocellular Carcinoma in AL-Beiruny University Hospital
Abstract
Background: Hepatocellular carcinoma is one of the most common types of cancer and its treatment depends on the clinical stage, tumor extension, hepatic function, and associated pathologies. Treatments vary by surgery, liver transplantation, or local treatments such as cryotherapy, intra-arterial injection or radiotherapy, and systemic therapy can be used. Sorafenib is the only treatment given as a first line in advanced or metastatic HCC. Studies have shown that administration of sorafenib has given benefit in terms of response, disease control and overall survival, especially when it is Child-Pugh A.
The aim of this study: The research aims to study the efficacy and adverse effects of SORAFENIB in patients with HCC
Methods: An interventional study of a clinical trial model was conducted i at Al-Biruni University Hospital in 2010 on 32 patients.
Results: 32 patients with hepatocellular carcinoma participated in the study, 85% male and 15% female, who were followed up in two phases after application at 3 months and 6 months. Within 3 months (37.5%) partial response, (28.12%) remission, and disease progression (21.87%) After 6 months (15%) complete response, (25%) partial response (28.12%) stable disease and (12.5%) disease progression. Hand and foot skin reactions (37.5%) and diarrhea (31.25%) were the most common adverse effects.
Conclusion: Sorafenib is a valid treatment option for advanced liver cancer. Dose reduction is still a better solution to side effects than stopping or replacing the drug, and deserves further extensive studies
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
